$ALDX

Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001341235 0001341235 2026-07-28 2026-07-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28,

Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001341235 Massachusetts 0001341235 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event report

Brady Todd C (President and CEO) purchased 250,000 shares of Aldeyra Therapeutics, Inc. (ALDX) at $1.67 ($0.42M total) on 2026-06-03.

Aldeyra Therapeutics said it is reviewing FDA feedback on its dry eye drug reproxalap after receiving a CRL. CEO Brady said the FDA cited five trials, with disagreement on three; Aldeyra may use the FDA’s Formal Dispute Resolution process. He estimated any extra dry-eye trials could cost ≤$5M each. Aldeyra reported $65M cash and expects runway into H2 2028.

Aldeyra Therapeutics, Inc. (ALDX) has filed its quarterly earnings report (10-Q) for the period ended March 31, 2026, revealing a net loss of $3.5 million, a significant improvement from $9.9 million in the same period last year due to decreased research and development and general and administrative expenses. The company's cash and cash equivalents stood at $65.0 million, and it anticipates these funds will be sufficient to cover operating expenses and debt obligations into the second half of 2028. Aldeyra is highly reliant on the successful commercialization of reproxalap, currently awaiting potential FDA approval, and acknowledged risks associated with regulatory hurdles, intense competition, and the necessity of securing additional funding for future development and commercialization efforts.

Kirby McInerney LLP reminds investors of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) about the May 29, 2026 deadline to become a lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Aldeyra failed to disclose inconsistent results from clinical trials of its drug candidate, reproxalap, leading to a significant stock price drop following a Complete Response Letter from the FDA. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, are encouraged to contact the firm to discuss their rights.

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) alleging that the company made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. The lawsuit covers investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026. Investors who suffered losses are encouraged to join the case, with a lead plaintiff deadline of May 29, 2026.

The Schall Law Firm is notifying investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged securities fraud. The lawsuit claims that Aldeyra made false and misleading statements regarding inconsistent clinical trial results for its reproxalap drug candidate. Investors who purchased securities between November 3, 2023, and March 16, 2026, are encouraged to contact the firm by May 29, 2026, to potentially lead the lawsuit.

The Schall Law Firm has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged securities fraud between November 3, 2023, and March 16, 2026. Investors who purchased Aldeyra securities during this period and suffered losses are encouraged to contact the firm to discuss their rights and potentially lead the lawsuit. The complaint asserts that Aldeyra made false and misleading statements regarding inconsistencies in clinical trials for its reproxalap drug candidate, causing investor damages.

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) CEO Todd C. Brady was granted 1,880,510 stock options with an exercise price of $1.77 per share and 632,318 bonus units. These awards are part of his compensation package and are subject to vesting schedules contingent on continuous service to the company. The stock options vest monthly over 48 months, and the bonus units vest annually over four years, with the vested units entitling him to a cash payment based on the common stock's closing price.